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MDA-MB453 cellBreast cancer is the second leading cause of death in women and thus has received a great deal of attention by
researchers. Recent studies suggested decreased occurrence of cancer in patients treated with cardiac glyco-
sides (CGs) for heart conditions. Because CGs induce their cellular effects via the Na+, K+ ATPase (Na–K), we
treated four breast cancer cell lines (MCF-7, T47D, MDA-MB453, and MDA-MB231) and a non-cancerous
breast ductal epithelial cell line (MCF-10A) with ouabain, a well-characterized CG, and measured cell prolif-
eration by measuring bromodeoxyuridine incorporation. Ouabain (1 μM) decreased cell proliferation in all
cell lines studied except MDA-MB453 cells. Western blot of Na–K α and β subunits showed α1, α3, and β1
expression in all cell lines except MDA-MB453 cells where Na–K protein and mRNA were absent. Potassium
uptake, measured as rubidium (86Rb) ﬂux, and intracellular potassium were both signiﬁcantly higher in
MDA-MB453 cells compared to MCF-10A cells. RT-qPCR suggested a 7 fold increase in voltage-gated potassi-
um channel (KCNQ2) expression in MDA-MB453 cells compared to MCF-10A cells. Inhibition of KCNQ2
prevented cell growth and 86Rb uptake in MDA-MB453 cells but not in MCF-10A cells. All cancer cells had
signiﬁcantly higher vacuolar H-ATPase (V-ATPase) activity than MCF-10A cells. Inhibition of V-ATPase de-
creased 86Rb uptake and intracellular potassium in MDA-MB453 cells but not in MCF-10A cells. The ﬁndings
point to the absence of Na–K, high hERG and KCNQ2 expression, elevated V-ATPase activity and sensitivity to
V-ATPase inhibitors in MDA-MB453. We conclude that cancer cells exhibit fundamentally different metabolic
pathways for maintenance of intracellular ion homeostasis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
As drug-resistant cancer has become more prevalent, so has the
push to develop novel chemotherapeutics. Cardiac glycosides (CGs)
have been used to treat malignancies dating back to the 8th century
[1]. More recently, Stenkvist et al. [2,3] followed 175 patients in a
22.3 year case study with a breast carcinoma, where 32 were being
treated with digitalis at the time of diagnosis. In the patients that
were undergoing digitalis treatment, there was a signiﬁcantly lower
death rate compared to patients not treated with digitalis (6% vs.
34%). Additionally, digitalis patients exhibited a recurrence rate 9.6
times lower than non-digitalis patients [4]. Chen et al. [5] using an in-
ternal dose response analysis of data from 9271 patients with cardiac
disease sex matched with controls from the Norwegian Cancerxter Bldg. Room 102, University
1160; fax: +1 502 852 4384.
Khundmiri).
l rights reserved.Registry demonstrated signiﬁcant relationship between high plasma
levels of digitoxin and a decreased risk for leukemia/lymphoma and
kidney/urinary tract cancers.
CGs bind to and inhibit theNa+, K+ATPase (Na–K), a heterotrimeric
P-type ATPase consisting of α, β and γ-subunits. Na–K transports Na+
and K+ against their concentration gradients in a 3:2 stoichiometry.
The gradients maintained by Na–K allow for the secondary transport
of many organic and inorganic substances, osmotic regulation and ion
homeostasis. Approximately 30% of the cell's resting energy consump-
tion is due to the action of Na–K [4]. To date four isoforms of the
α-subunit, three isoforms of the β-subunit and seven isoforms of the
γ or FXYD subunit have been described [6]. Expression of the subunits
is tissue speciﬁc, except forα1 andβ1which are ubiquitously expressed
[7,8]. In addition to its pump functions, Na–K is now recognized as
a scaffold to form a complex “signalosome” that activates several
different signaling pathways such as the MAP kinase and PI3 kinase
pathways. CGs elicit activation of signaling cascades in the cell that ac-
tivates both pro-survival and pro-apoptotic pathways depending upon
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pro-survival pathways in kidney cells [9] and at high doses activate
caspases in cancer cells [10–13]. In rodent models CGs had no effect
on cell proliferation while in monkey and human cancer cells they acti-
vate pro-apoptotic pathways [14].
Studies have found altered expression and activity of Na–K sub-
units in various cancers; e.g., colon, lung, and hepatocellular carcino-
ma. Sakai et al. demonstrated that an increased α3:α1 ratio occurs in
colon tissue during normal to malignant transition [14,15]. Shibuya et
al. suggest the upregulation of α3 as the cause for increased pump ac-
tivity and CG sensitivity in hepatocellular carcinoma [16]. In contrast,
Mijatovic et al. [17] found that lung carcinomas overexpressing α1
were more sensitive to certain CGs. Decreased β subunit expression
has been observed in a number of cancers [18–20]. Na–K β subunits
are involved in cell to cell interactions, and decreased expression
has been reported for a number of cancers implicating a possible
role in epithelial to mesenchymal transformation that is seen in ma-
lignancies [5,18–20]. These differential alterations in Na–K expression
in cancer cells may account for the differential sensitivity reported for
CGs, possibly through disruption of the Na–K “signalosome” [14,17].
The present study examines the effect of CGs on proliferation of
breast cancer cells. Our data suggest that ouabain does not exert a
preferential effect on cancer cell growth as it decreased cell prolifera-
tion in both cancerous and non-cancerous cells. In fact, we showed an
increase in activity of vacuolar H+-ATPase in cancer cells suggesting
that this transport protein may be a more directed target for anti-
cancer therapy than Na–K. Interestingly, we also demonstrated
that the highly metastatic breast cancer line, MDA-MB453, did not ex-
press Na–K, relying instead on V-ATPase to maintain intracellular ion
homeostasis.
2. Methods
2.1. Materials
All cell culture media and bovine serum were purchased from
Invitrogen. PP2, LY290859, dofetilide, insulin, hydrocortisone, epider-
mal growth factor, and phosphatase and protease inhibitor cocktails
were purchased from Sigma (St. Louis, MO). Ouabain, SCH28080, and
10, 10-bis (4-pyridinylmethyl)-9(10H)-anthracenone dihydrochloride
(XE-991) were purchased from Tocris Bioscience (Ellisville, MO). BrdU
cell proliferation kit was purchased from Abnova. mRNA isolation kit
and mRNA to cDNA kit were purchased from Applied Biosystems. Taq
DNA polymerase was purchased from BioRad. Quantitative PCR array
kit, RT-proﬁler array for human neuroscience ion channels and trans-
porters (catalog no. PAHS 036A) were purchased from SA Biosciences.
Monoclonal antibodies against Na–K α1 and β1 subunits were pur-
chased from RBI-Sigma. Antibodies against Na–K α2, α3, and β2 were
purchased from Upstate (Lake Placid, NY).Table 1
Cells.
Cell Type Organ Disease
MCF-10A Mammary gland, breast Fibrocystic disease
MCF-7 Mammary gland, breast Adenocarcinoma
T47D Mammary gland, ductal tissue Ductal carcinoma
MDA-MB231 Mammary gland, breast Adenocarcinoma
MDA-MBMB453 Mammary gland, breast Metastatic carcinoma
OK Opossum kidney None
a ER — estrogen receptor expression.2.2. Cell culture
Experimental procedures were performed using MCF-10A, MCF-7
and MDA-MB453 (gifts from Dr. Roland Valdes, University of Louisville),
T47D (a gift from Dr. Carolyn Klinge, University of Louisville) and
MDA-MB231 cells (ATCC). The opossum kidney (OK) cells, a continuous
cell line derived from Virginia opossum for mammalian renal proximal
tubule [9] were a kind gift from Dr. Steven Scheinman (Health Sciences
Center, Syracuse, NY). The estrogen receptor expression status and
tumorigenic characteristics of the cells are shown in Table 1. The
MCF-10A,MCF-7 andMDA-MB231 cellswere grown inmedia containing
DMEM-F12 (1:1) supplementedwith 5% fetal bovine serum (Invitrogen),
1% penicillin/streptomycin (Invitrogen), 834 μg/L insulin (Sigma), 0.5 μM
hydrocortisone (Sigma) and 220 ng/L human epidermal growth factor
(Sigma). The T47D and MDA-MB453 cells were maintained in RPMI
1640, supplemented with 5% FBS and insulin. OK cells were grown in
Minimum Essential Medium with Earle's salts supplemented with 10%
FBS and 1% penicillin/streptomycin.
2.3. Ouabain treatment
Stock ouabain (10 mM) was dissolved in DMSO and diluted in
serum-free medium to get the required concentration as shown in
Results. The ﬁnal DMSO concentration was less than 0.1%. Unless
otherwise stated, cells were treated with ouabain for 24 h at 37 °C
in a humidiﬁed incubator (95% air/5% CO2). Control cells were treated
with 0.1% DMSO.
2.4. Cell proliferation assay
The cell lines were subcultured in 96-well plates at a density of
10,000 cells/well. Once the cells reach approximately 20% conﬂuence,
they were serum deprived (respective media supplemented with 1%
serum) for 24 h, then treated with various concentrations of ouabain
for 48 h. In the last 15 h of treatment, bromodeoxyuridine (BrdU)
was added to the wells for incorporation into the DNA following
manufacturer's instructions (BrdU ELISA kit, Abnova). The cells were
ﬁxed, washed, incubated with the monoclonal anti-BrdU primary an-
tibody for 1 h at room temperature. The cells were washed and incu-
bated for 30 min with HRP-conjugated secondary antibody. The
absorbance measured at 450/540 nm is proportional to BrdU incorpo-
ration. The data are expressed as absorbance at 450/540 nm and an-
alyzed by ANOVA followed by Bonferroni analysis.
2.5. Rubidium uptake
To assess potassium transport, 86Rb uptake was performed as de-
scribed previously [9]. Conﬂuent serum deprived monolayers of
breast cancer or MCF-10A cell lines grown on 24 well plates wereTumorigenic Metastatic ERa
+/−
No No −
[44,45]
Yes (with estrogen supplement) Yes (pleural effusion) +
[44,45]
Yes (with estrogen supplement) Yes (pleural effusion) +
[44,45]
Yes Yes (pleural effusion) −
[44,45]
No Yes (involving nodes, brain,
pericardial, pleural cavities)
−
[44,45]
No No +
[46]
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cubated for 10 min in 1 μCi of 86Rb, washed four times with PBS, and
lysed overnight at 37 °C in a PBS containing 0.5 N NaOH and 0.1%
Triton-X100. An aliquot of 100 μL of sample was used to measure radio-
activity with scintillation counter and 50 μL of the sample was used to
measure protein. The radioactivity counts were normalized to protein
concentration. Rb uptake is expressed as nmoles Rb/mg protein/10 min
or as percent change from the vehicle treated cells.
2.6. Measurement of cell sodium and potassium
Cell sodium or potassium was measured as described previously
following the method described by Hou and Delamere [9,21]. The
cell monolayers were washed with ice-cold isotonic magnesium chlo-
ride solution (100 mMMgCl2, adjusted to pH 7.4 with Tris base). The
magnesium chloride solution was removed and 200 μL of 30% nitric
acid was added to each well to digest the cells. After this, 1.8 mL de-
ionized water was added to each well and the sodium and potassium
content of the diluted cell lysates was measured using an atomic ab-
sorption spectrophotometer (Perkin-Elmer, Norwalk, CT) at a wave-
length of 566.5 nm. Intracellular sodium and potassium content is
expressed as 10−9 mol/μg protein.
2.7. Crude membrane isolation
Cells were lysed in homogenization buffer containing 300 mM
mannitol, 5 mM Tris-HEPES, and a 1:500 dilution of phosphatase
and protease inhibitor cocktails (Sigma). Cell lysates were centrifuged
at 780 ×g for 5 min to remove nuclei and cell debris. The supernatant
was collected and centrifuged at 30,000 ×g for 45 min and the crude
membrane pellet was resuspended in homogenization buffer by pass-
ing ten times through a 26 1/2 gauge needle. In some experiments
nuclear free cell lysate was used to determine total Na–K ATPase ex-
pression in the control and cancer cells.
2.8. Western blot analysis
Western blots were performed as described previously [9].
2.9. mRNA isolation and RT PCR
mRNA was isolated from MCF-10A and MDA-MB453 cells grown in
75 cm3 ﬂasks using Ambion's mirVana™ mRNA Isolation Kit (Ambion
catalog # AM1561) according to the manufacturer's protocol. Eluted
RNA was stored overnight at −80 °C. RNA concentrations were deter-
mined using the DU730 Life Sciences UV/Vis Spectrophotometer
(Beckman Coulter) and cDNA was synthesized using mRNA to cDNA kit
(Applied Biosystems). Brieﬂy, 4 μL high capacity RNA-to-cDNA Master
Mix and 10 ng RNA template were added to a fresh PCR tube along
with enough nuclease-free water for 20 μL total volume. Reverse tran-
scription was performed using oligodT primers in Biorad MyCycler™
thermal cycler programmed to the following conditions: 37 °C — 1 h,
95 °C — 10 min, and 4 °C — 30 min. The cDNA samples were stored at
−80 °C. PCR was performed in 20 μL volume containing 1 unit Biorad
iProof™ High-Fidelity DNA polymerase, 5 mMMgCl2, 1 mM dNTPs, and
200 nM each of forward and reverse primers speciﬁc for Na–K α1, α2,
or α3 and 4 μL cDNA or water (negative control) at the following condi-
tions: 98 °C — 1 min, (94 °C — 1 min, 50 °C — 1 min, 72 °C — 1 min)
35×, 72 °C — 5 min. The primer sequences for human Na–K α1 were
GAAAGAAGTTTCTATGGA TG (forward) and ATGATTACAACGGCTGATAG
(reverse, 318 bp product); for α2 were AGAGAATGGGGGCGGCAAGAAG
(forward) and TGGTTCATCCTCCATGGCAGCC (reverse, 322 bp product);
and for α3 were CCTCACTCAGAACCGCATGAC (forward) and TTCATCA
CCAGCAGGTATCGG (reverse, 384 bp product). The PCR products were
separated by 1% agarose gel electrophoresis and visualized usingethidium bromide. Data were analyzed by ImageQuant using
Typhoon.2.10. Quantitative RT-PCR
Total RNA was isolated as described above. RNA was reverse tran-
scribed using oligodT primers as described above. Quantitative PCR was
performed using RT-proﬁler array for human neuroscience ion channels
and transporters (catalog no. PAHS 036A) and RT-SYBR green/ROX PCR
master mix (catalog no. 330520, SA Biosciences, Frederick, MD) in
Applied Biosystems 7500 quantitative PCR thermocycler according to
the manufacturer's protocol. The transporters/channels are listed in
Supplementary Table 1. Expressionwas quantiﬁed by themanufacturer's
protocol as fold change relative to 18s RNA expression. Data were ana-
lyzed using SA Biosciences online software.2.11. Baﬁlomycin A1 sensitive ATPase activity
Baﬁlomycin A1-sensitive ATP hydrolysis was assayed by measur-
ing the production of inorganic phosphate as described previously
[22] following the method described by Lu et al. [23]. Cells were
lysed, crude membranes were prepared and ATPase activity was mea-
sured in the presence or absence of 1 mM baﬁlomycin A1, a maximal
V-ATPase inhibitory concentration. Brieﬂy, crude membranes were
incubated in ATPase buffer containing 150 mM NaCl, 2 mM MgCl2,
1 mM sodium vanadate, and 1 mM sodium azide (pH 6.75) for
15 min at room temperature in the presence and absence of 1 mM
baﬁlomycin A1. The reaction was initiated by addition of ATP at a
ﬁnal concentration of 3 mM and incubated for 30 min at 37 °C. The
reaction was stopped by addition of trichloroacetic acid. The samples
were extracted with equal amount of chloroform to remove lipid and
detergent. The samples were centrifuged at 10,000 rpm for 20 min at
room temperature. The upper aqueous phase was transferred to clean
test tubes and inorganic phosphate released was measured as de-
scribed previously [22]. The difference in the ATPase activity assayed
in the absence and presence of 1 mM baﬁlomycin A1 is taken as a
measure of vacuolar H+-ATPase activity. Vacuolar H+-ATPase activity
is expressed as μmoles Pi released per milligram protein per hour.2.12. Protein determination
Protein concentration of samples was determined using a
bicinchoninic acid protocol (Sigma) using bovine serum albumin as
a standard.2.13. Statistics
The data are presented as either SD or SEMwhere the n value repre-
sents the number of replicates. p values were obtained using GraphPad
Prism software employing a two-way ANOVA followed by Bonferroni's
post hoc analysis. Signiﬁcance was established by a p value b 0.05.3. Results
3.1. Cell morphology
To determine if ouabain changes cell morphology, cells were plated
on 8-well glass chambers and treated for 24 h with 100 nM or 1 μM
ouabain. As shown in Fig. 1, treatment with ouabain had no consistent
effect on gross morphology in any of the cancer cell lines studied. How-
ever, treatment with 1 μM ouabain caused the MCF-10A cells to shrink
and become rounded.
Vehicle
Ouabain (100 nM)
Ouabain (1 µM)
MCF-10A MCF-7 T47D MDA-453 MDA-231
Fig. 1.Morphological features of breast cells. As described in Table 1, MCF-10A cells are non-cancerous from ﬁbrocystic disease patient. MCF-7 and T47D cells are estrogen positive
cells from breast carcinoma while MDA-MB231 and MDA-MB453 are estrogen negative cells from breast carcinoma. Cells were treated for 24 h with either 100 nM or 1 μM ouabain
at 37 °C in a humidiﬁed 5% CO2/95% air incubator. Transmission light microscopy was performed using Olympus FV1000 microscope using an oil immersion 60× objective lens.
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To determine the effects of ouabain on cell proliferation, estrogen
receptor positive (MCF-7 and T47D) and negative (MDA-MB453 and
MDA-MB231) breast cancer cell lines and a non-cancerous, breast
ductal epithelial cell line (MCF-10A) were treated for 0–4 days with
100 nM (a concentration close to IC50 for human Na–K α subunits)
or 1 μM (an inhibitory concentration) ouabain. There was no signiﬁ-
cant inhibition of cell proliferation with 100 nM ouabain (Fig. 2A).
Treatment with 1 μM ouabain decreased cell proliferation in all cell
lines except MDA-MB453 cells by day 2 (Fig. 2B). Ouabain had no ef-
fect on cell proliferation in MDA-MB453 cells at either concentration.
3.3. Effect of ouabain on rubidium uptake
Because ouabain binds to and elicits its effects through Na–K [7], we
tested the effects of 100 nM or 1 μM ouabain on total rubidium (86Rb)
uptake in MCF-10A and the four cancer cell lines. Treatment with
100 nM or 1 μM ouabain for 24 h signiﬁcantly inhibited 86Rb uptake
in all cell lines except MDA-MB453 cells. Notably, 86Rb uptake in the
MDA-MB453 cancer cell line was two-fold greater than all the cells
studied (Fig. 3A). MDA-MB453 cells had a signiﬁcantly higher intracel-
lular potassium concentration compared toMCF-10A cells (Fig. 3B). It is
noteworthy that in both MCF-10A cells and MDA-MB453 cells sodium
was roughly equivalent.
3.4. Na–K expression
The inability of ouabain at 1 μM concentration to inhibit prolifera-
tion of MDA-MB453 cells suggests that these cells might have an ab-
normal Na–K ATPase expression and function. Western blot analysisof crudemembrane preparations demonstrated an unexpected absence
of all tested Na–K subunits in the MDA-MB453 cells (Fig. 4A–C). The
MCF-10A, MCF-7, T47D and MDA-MB231 cell lines expressed the α1,
α3 and β1 subunits of Na–K. The α2 and β2 subunits were not detect-
able in any of the cell lines (data not shown). The pattern of expression
of NHE-1 was not unusual in any of the cells studied (Fig. 4D). To
determine if the lack of Na–K expression inmembranewasdue to a traf-
ﬁcking defect, we performedWestern blot on whole cell homogenates,
and as shown in Fig. 4A–C (right panel) therewas no detectable expres-
sion of any Na–K subunits in the MDA-MB453 cells. Additionally, there
was a signiﬁcant decrease in Na–K α1 expression in the T47D and
MDA-MB231 cells, while the expression of Na–K α3 increased in the
cancer lines relative toMCF-10A. The ratio of Na–Kα3 toα1was higher
in MCF-7, T47D, and MDA-MB231 cells as compared to MCF-10A cells
(Fig. 4E).
To further examine the apparent absence of Na–K protein expres-
sion, we isolated mRNA from MCF-10A and MDA-MB453 cells, and
performed qualitative RT-PCR. As shown in Fig. 4F, MCF-10A cells
expressed mRNA for Na–K α1 and α3 while there was no detectable
Na–K α1 or α3 mRNA in MDA-MB453 cells.
Consistent with the lack of Na–K expression, evidence of Na–K de-
pendent signaling cascade activation was absent in MDA-MB453 cells.
As shown in Fig. 5, treatment for 15 min with 100 nM ouabain in-
creased Src, ERK1/2, and Akt phosphorylation in MCF-10A cells but
not in MDA-MB453 cells (Fig. 5). These data support the absence of
a functional Na–K in MDA-453 cells.
3.5. SCH28080 sensitive 86Rb uptake
The increased level of 86Rb uptake in MDA-MB453 cells despite the
absence of Na–K suggests that an alternative K+ transport mechanism
Fig. 2. Effect of ouabain on cell proliferation in breast cancer cells. Cells were treated
with 100 nM (A) or 1 μM (B) ouabain for the indicated time. Cell proliferation was
measured as BrdU incorporation in the DNA as described in Methods. Each bar repre-
sents data as mean ± se from 3 separate experiments (n = 3). In each experiment
data was pooled from 12 repeats and the average was considered as one data point.
* indicates signiﬁcantly different (p b 0.05 by ANOVA) from the respective 0 day
time point.
Fig. 3. Basal 86Rb uptake and intracellular Na and K concentrations. A, cells were treat-
ed for 24 h with 100 nM or 1 μM ouabain and potassium uptake was measured as 86Rb
uptake in breast cancer cells. Each bar represents data as mean ± se from 4 separate
experiments (n = 4). In each experiment data was pooled from 3 repeats and the av-
erage was considered as one data point. * indicates signiﬁcantly different (p b 0.05 by
ANOVA) from the respective vehicle (0) treated group. B, basal intracellular Na and K
content was measured as described in Methods. The data are presented as 10−9 mol/μg
protein. Each bar represents data as mean ± se from 3 separate experiments (n = 3).
* indicates signiﬁcantly different (p b 0.05 by ANOVA) fromMCF-10A cells. Note logarith-
mic scale on y-axis in panel B.
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bind ouabain and bears structural similarities to Na–K [24], we investi-
gated the contribution of H+–K+ ATPase to K+ transport in the breast
cancer cells (Fig. 6A). By completely inhibiting Na–K using 10 μM oua-
bain, we determined that Na–K contributes approximately 50% of
86Rb uptake in the MCF-10A, MCF-7 and MDA-MB231 cells; 75% in
T47D cells; and 0% in MDA-MB453 cells. These ﬁndings are consistent
with the total absence of Na–K protein and mRNA expression in
MDA-MB453 cells. Inhibition of both gastric and non-gastric H+–K+
ATPase with 20 μM SCH28080 failed to inhibit 86Rb uptake in any of
the cell lines. Thus it is not likely that H+–K+ATPase is a major contrib-
utor to K+ transport in breast cancer cells. Similar results were obtained
with omeprazole, a different inhibitor of H+–K+ ATPase (data not
shown). Additionally, inhibition of NKCCwith bumetanide had no effect
on 86Rb uptake (data not shown).
3.6. Ion channel/transporter qPCR array
To identify the potassium transporter/channel responsible for the in-
creased 86Rb uptake we performed ion channel/transporter qPCR array.
Transporters increased in MDA-MB453 cells relative to MCF-10A are
shown in Table 2. The expression of hERG (KCNH2, 14.78 fold), voltage-
gated potassium channel of KQT subfamily member 2 (KCNQ2, 7.076
fold), inwardly-rectifying potassium channel (KCNJ4, 4.678 fold),voltage-gated potassium channel of Shab-related family (KCNB1, 3.613
fold), and Shaw-related subfamily (KCNC4, 3.161 fold) increased com-
pared to MCF-10A cells. There was no differential expression of Na–K
ATPase β1 subunit (ATP1B1, 1.21 fold), voltage-gated calcium channel
(CACNA1A, 0.652 fold) and SLC6A3 (0.591) inMDA-MB453 cells. The ex-
pression of voltage-gated potassium channels of shaker-related family 1
(KCNA1, 0.0431 fold) and 4 (KCNA4, 0.218 fold), voltage-gated potassi-
um channel G subfamily 1 (KCNG1, 0.0986 fold), voltage-gated potassi-
um channel KQT subfamily 4 (KCNQ4, 0.0004 fold), and voltage gated
sodium channel type IX (SCN9A, 0.145 fold) decreased compared to
MCF-10A cells. Consistent with our Western blot data, Na–K α1
(0.0002 fold) was not detected in MDA-MB453 cells. It is noteworthy
that, H+, K+ ATPase (ATP4A, 0.0006 fold) was undetectable in MDA-
MB453 cells, consistent with lack of effect of SCH28080.
3.7. Dofetilide-sensitive 86Rb uptake
The hERG channel is a voltage-gated K+ channel found to have 14
fold increased mRNA expression in MDA-MB453 cancer cell lines as
compared to the MCF-10A cells (Table 2) [25]. Wang et al. [26] dem-
onstrated that ouabain at nanomolar concentrations inhibits hERG
channel. We therefore, investigated the role of hERG using the specif-
ic hERG inhibitor, dofetilide, in 86Rb uptake studies. We found a
Na-K α1
β-Actin
A
100
50
100
1.105 ± 0.989± 0.641 ± 0.004 ± 0.953±
0.062       0.084    0.099      0.001 *   0.213
MCF-10A   MCF-7  T47D   MDA-453  MDA-231
0.79± 1.197 ± 1.091 ± 0.001 ± 0.986 ±
0.0497      0.237       0.41        0.001*       0.11
Membrane Cell Lysates
Na-K α3
Na-K β1
B
C
0.316± 2.026 ± 1.771 ± 0.003 ± 1.19 ±
0.093         0.822       0.927       0.001 *      0.157
100
50
β-Actin
50
50
β-Actin
0.76± 2.2 ± 1.219 ± 0.004 ± 1.299 ±
0.092          0.588      0.509      0.001*     0.209
MCF-10A     MCF-7    T47D   MDA-453   MDA-231
100
0.601 ± 0.915± 0.861 ± 0.001 ± 1.054±
0.112       0.138    0.145     0.001*    0.095
50
1.06 ± 1.248± 0.561 ± 0.005 ± 1.357±
0.162      0.392    0.137     0.001 *   0.305
50
50
50
D E
NHE-1
100
50 β-Actin
0.759 ± 1.015± 0.454 ± 0.464 ± 0.931±
0.058        0.079        0.062      0.041     0.081
Na-K α1
Na-K α3
312bp
384bp
F
380bp GAPDH
MCF-10A   MCF-7      T47D   MDA-453    MDA-231
Fig. 4. Expression of Na–K ATPase in crude membranes and cell homogenates. Membrane expression of Na–K ATPase α1 subunit (A), α3 subunit (B), and β1 subunit (C) in crude
membranes (left panel) or in homogenates (right panel). Expression of NHE-1 in crude membrane preparation (D). A representative Western blot is shown. Values mean ± se rep-
resent data as arbitrary units (ratio of protein expression to actin expression) from 4 separate experiments. * indicates signiﬁcantly different (p b 0.05 by ANOVA) from the
MCF-10A cells. E, ratio of Na–K α3:α1 membrane expression. Each bar represents mean ± se data as ratio of α3:α1 expression data from A and B. * indicates signiﬁcantly different
(p b 0.05 by ANOVA) from the MCF-10A cells. F, mRNA expression of Na–K α1 (upper panel) α3 (middle panel), and GAPDH (lower panel) was measured by RT-PCR as described in
Methods. Representative gel from 4 different experiments is shown.
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non-cancerous MCF-10A cells only (Fig. 6B). Dofetilide had no effect
on 86Rb uptake in any cancer line tested. This indicates that the
hERG channel is not likely to contribute to potassium ﬂux (86Rb up-
take) in MDA-MB453 cells.
3.8. Effect of KCNQ2 inhibition on cell proliferation
Because the increase in KCNQ2 expression was higher (7.3 fold)
than the other potassium channels except hERG, we examined the
role of KCNQ2 in cell proliferation and 86Rb uptake in MCF-10A and
MDA-MB453 cells. Cells were treated for 24 h or 48 h with a speciﬁc
KCNQ2 inhibitor (8 μM XE-991, IC50 800 nM) and cell proliferation
and 86Rb uptake were measured. As shown in Fig. 7A, treatment
with XE-991 had a small but signiﬁcant effect on cell proliferation
in MDA-MB453 cells but not in MCF-10A cells. 86Rb uptake was alsopartially inhibited by XE-991 in MDA-MB453 cells but not in MCF-
10A cells (Fig. 7B).
3.9. Vacuolar ATPase (V-ATPase) activity
Because the V-ATPase proton pump is electrogenic it could feasibly
establish electrical potential in cells that lack Na–K expression [27–29].
To examine V-ATPase activity we determined baﬁlomycin-sensitive
ATP hydrolysis in crude membrane preparations of the breast cancer
cells and compared the activity with renal proximal tubule (OK) cells
from opossum kidney. As shown in Fig. 8, all breast cell lines had a sig-
niﬁcantly higher V-ATPase activity compared to kidney cells. Basal
V-ATPase activity in crude membrane preparations was signiﬁcantly
higher in all cancer cell lines as compared to non-cancerous MCF-10A
cells. To determine if V-ATPase provides sufﬁcient electrical potential
to drive potassium uptake in MDA-MB453 cells, 86Rb uptake was
Phospho-Src Y416
Total-Src
Phospho-ERK1/2
Phospho-Akt-S473
Total-ERK
Total-Akt
50
50
50
50
50
50
MDA-453 MCF-10A
Ouabain (100 nM)  - +            - +   
1.30± 1.45 ± 0.26 ± 0.649 ±
0.122       0.199     0.04         0.072*
0.716± 0.53 ± 0.66 ± 1.017 ±
0.266       0.231     0.066        0.069*
0.72± 0.984 ± 0.54 ± 0.91 ±
0.122       0.138      0.07         0.12*
Ratio p-Src : t-Src
Ratio p-ERK p42 : t-ERK
Ratio p-Akt : t-Akt
Fig. 5. Effect of ouabain on Src, ERK, and Akt phosphorylation. Cells were treated for
15 min with 100 nM ouabain, lysed in buffer containing 50 mM mannitol, 5 mM
Tris-HEPES pH 7.4, 0.1% Triton X-100, 0.5% SDS, 0.5% NP40, and 10 μL/100 μL phospha-
tase and protease cocktails, and centrifuged at 14,000 ×g for 15 min. Supernatant pro-
teins (50 μg/lane) were separated by 10% SDS-PAGE, transferred to nitrocellulose
membranes. Proteins were detected using phospho-speciﬁc antibodies. Membranes
were stripped and reprobed with antibodies to total proteins. A representative West-
ern blot from 4 independent experiments is shown. Values mean ± se represent
data as arbitrary units (ratio of phospho-protein expression to total protein expres-
sion) from 4 separate experiments. * indicates signiﬁcantly different (p b 0.05 by
ANOVA) from the vehicle treated cells.
Table 2
Expression of different ion channels in MDA-MB453 cells as compared to MCF10A cells.
Protein Fold expression levels from MCF-10A
ATP1A1 (Na–K ATPase α1) 0.0002
ATP1B1 (Na–K ATPase β1) 1.2101
ATP4A (H–K ATPase) 0.0006
CACNB3 3.2009
CFTR 0.0004
CLCA1 0.0003
CLCNC3 0.3779
CLCNC6 7.1384
KCNA1 0.0431
KCNB1 3.16133
KCNC4 2.1807
KCNH4 (hERG) 14.7823
KCNJ4 4.67839
KCNQ2 7.0763
SLC2A1 (GLUT1) 11.9853
SLC18A2 3.8605
(A complete list of ion transporters is presented as Supplementary Table 2.)(A
complete list of ion transporters is presented as Supplementary Table 2.)
Fig. 6. Effect of H+–K+ ATPase and hERG on total 86Rb uptake. Cells were treated for
24 h with 20 μM SCH28080, an H+–K+ ATPase inhibitor (A) or 100 nM dofetilide, an
inhibitor of hERG (B). Total potassium uptake was measured as 86Rb uptake as de-
scribed in Methods. Each bar represents data as mean ± se percent residual uptake
from vehicle treated group from 3 individual experiments (n = 3). In each experiment
data from 4 repeats was averaged and considered as one data point. * indicates signif-
icantly different (p b 0.05 by ANOVA) from the respective vehicle treated group.
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A1 or 50 nM concanamycin A. As shown in Fig. 9A, 24 h treatment
with baﬁlomycin A1 or concanamycin A completely abolished 86Rb up-
take (Fig. 9A, upper panel). The same baﬁlomycin A1 and concanamycin
A treatment caused a very large decrease in intracellular potassium
content (Fig. 9B, upper panel). Interestingly, 30 min treatment with
baﬁlomycin A1 or concanamycin A had no effect on 86Rb uptake
(Fig. 9A, lower panel).
4. Discussion
In the present study, we demonstrate a remarkable variability in the
expression of transport proteins involved in the maintenance of intra-
cellular ion homeostasis in a series of benign and malignant breast epi-
thelial cells, with correlation to phenotypic features. We identiﬁed a
two-fold greater potassiumuptake and intracellular potassium content,
a complete absence of Na–K expression both at the protein and mRNA
level, and increased vacuolar H+-ATPase activity in a highly metastatic
cell line, MDA-MB453 cells, compared to a non-cancerous breast epi-
thelial cell line, MCF-10A and three other breast cancer cell lines. Our
data also demonstrate that the increased potassium uptake and intra-
cellular potassium inMDA-MB453 cells is dependent upon the electrical
potential driven by vacuolar H+-ATPase. The other three breast cancer
cells lines also exhibited variability in their expression of the Na–K sub-
units but all three showed an increase in vacuolar ATPase activity rela-
tive to the benign cell line.
As would be predicted from these ﬁndings, ouabain had no
anti-proliferative activity against MDA-MB453 cells but showed vari-
able antiproliferative effects on all of the other cells lines, both benign
and cancerous. Moreover, we show that ouabain does not speciﬁcally
decrease cell proliferation in cancer cells and its effect did not correlate
with the ER status or tumorigenicity. The cell lines most susceptible
to the anti-proliferative effects of ouabain were T47D, an ER positive,
tumorigenic, and metastatic cell and MDA-MB231, an ER negative,tumorigenic and metastatic cell. Our data demonstrate a differential ef-
fect of the cardioglycoside, ouabain, on multiple breast cancer cell lines
relative to a non-cancerous cell line, MCF-10A. Ouabain at a lower
concentration (100 nM) had no effect on cell proliferation in any of
the cell lines studied. At higher concentrations (1 μM), inhibition of
Fig. 8. Basal V-ATPase activity. V-ATPase activity was measured as baﬁlomycin A1
(1 mM)-sensitive ATP hydrolysis as described in Methods. Each bar represents data
as mean ± se from 3 individual experiments (n = 3). Each experiment was
performed in triplicate and the data were averaged and considered as one data point.
* indicates signiﬁcantly different (p b 0.05 by ANOVA) from activity in OK cells and #
indicates signiﬁcantly different (p b 0.05 by ANOVA) from activity in MCF-10A cells.
Fig. 7. Effect of KCNQ2 on cell proliferation and 86Rb uptake. MCF-10A or MDA-MB453
cells were treated with XE991, an inhibitor of KCNQ2 for 24 or 48 h. Cell proliferation
(A) or total potassium uptake as 86Rb uptake (B) was measured as described in
Methods. Each bar represents data as mean ± se from 3 individual experiments
(n = 3). In each experiment data from 4 repeats was averaged and considered as
one data point. * indicates signiﬁcantly different (p b 0.05 by ANOVA) from the respec-
tive vehicle treated group.
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with the exception of MDA-MB453 cells consistent with lack of Na–K
expression.
The absence of Na–K expression in the MDA-MB453 cells raises
the question of how these cells maintain normal intracellular homeo-
stasis. Intracellular K content was higher in MDA-MB453 cells than in
MCF-10A, but the content of Na was similar. The very high K ﬂux as
demonstrated by 86Rb uptake studies suggested a unique mechanism
for maintenance of intracellular ion balance. Because of the similari-
ties between Na–K and H+–K+ ATPase [24], we initially hypothesized
that this P type ATPase was responsible for the K uptake; however, in-
hibitor studies did not support this supposition. Quantitative RT-PCR
analysis showed the lack of H+, K+ ATPase expression in these cells
consistent with the lack of SCH28080 effect on 86Rb uptake. In a re-
cent study Wang et al. [26] demonstrated that hERG can bind to oua-
bain; however, inhibition of this inward rectifying potassium channel
by dofetilide had no effect on 86Rb uptake in any of the cancer cell
lines studied. The lack of effect of dofetilide on 86Rb uptake in all
the cancer cells may be explained by the fact that hERG generally per-
mits the passive movement of potassium ions out of the cell. Interest-
ingly, however, inhibition of 86Rb uptake in non-cancerous MCF-10A
cells by dofetilide may suggest that inhibition of hERG reduces the
rate of potassium exit causing the cell to suppress active potassium
uptake in order to maintain steady state. Our study for the ﬁrst time
suggests overexpression of the potassium channel KCNQ2 in highly
metastatic ER negative breast cancer cells (MDA-MB453). Inhibition
of KCNQ2 partially suppressed cell proliferation and 86Rb uptake in
MDA-MB453 cells but not in MCF-10A cells suggesting that KCNQ2
is responsible for at least some of the enhanced Rb ﬂux.
In eukaryotic cells V-ATPase energizes the transport of H+ ions into
the vacuoles and lysosomes for organelle acidiﬁcation. Using pharmaco-
logical inhibitors and RNAi several studies demonstrated the impor-
tance of plasma membrane V-ATPase in metastasis, cell proliferation,
pH homeostasis, and invasion in breast cancer cells [30–35]. Our data
showed signiﬁcantly higher V-ATPase activity in crude membrane
preparations from cancer cells compared to non-cancerous cells. Inter-
estingly, media from a day old culture of MDA-MB453 cells were very
highly acidic (data not shown), suggesting preferential localization of
V-ATPase to the plasmamembrane. The decrease in 86Rb uptake and in-
tracellular potassium in cells treated with speciﬁc V-ATPase inhibitors,
baﬁlomycin A1 and concanamycin A supports the notion that the
V-ATPase may establish the electrical potential required for transport
of potassium in the cancer cells. Providing the cells have a reasonably
high input resistance, the electrogenic, outwardly directed, active pro-
ton transport by V-ATPase would give rise to a negative membrane po-
tential that would favor K channel-mediated potassium accumulation.
The absence of an immediate effect in 30 min, however, also raises
the possibility that additional mechanisms for maintenance of the
high Rb ﬂux may exist.
The absence of all subunits of the Na–K in the MDA-MB453 cell
line may be a critical observation in understanding metastasis in can-
cer cells. Our data supports the work from Rajasekaran's laboratory
[18–20] that demonstrated the loss of Na–K in epithelial to mesen-
chymal transformation and metastasis. The absence of Na–K may ex-
plain the loss of cell–cell contact, morphology, and the highly
metastatic nature of these cells and could be an adaptation of cells
to escape the regulation by endogenous cardiac glycosides. Our ﬁnd-
ings are at odds with Einbond et al. [36] who reported that treatment
with the cardiac glycoside-like compound actein inhibited cell prolif-
eration by a mechanism that required activation of Src, Akt and Erk2
in MDA-MB453 cells. The authors suggested that actein acted through
inhibition of Na–K. While they did indeed observe Na–K activity inhi-
bition caused by actein, the ATPase assay was performed using a kit
that contains kidney microsomes which would be expected to ex-
press Na–K in high abundance. Considering the absence of Na–K in
MDA-MB453 cells and the high concentration of actein and digitoxin
Fig. 9. Effect of V-ATPase inhibition on total 86Rb uptake and intracellular Na and K concentrations. Cells were treated with 170 nM baﬁlomycin A1 or 50 nM concanamycin A for
30 min (A) or 24 h (B–D) and total 86Rb uptake (A and B) or intracellular K (C) or Na (D) were measured as described in Methods. Each bar represents data as mean ± se from 3
individual experiments (n = 3). Each experiment was performed in triplicate and the data was averaged and considered as one data point. * indicates signiﬁcantly different
(p b 0.05 by ANOVA) from respective vehicle treated cells. Note logarithmic scale on y-axis in panels C and D.
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effects of actein may not be linked to Na–K.
Several studies have demonstrated an inhibitory effect of cardiac
glycosides on a variety of cancers, including breast cancer, but have
not included comparison to non-cancerous cell lines [14,37–43]. We
were able to reproduce this inhibitory effect on the MCF-7, T47D, and
MDA-MB231 breast cancer cell lines, as well as the non-cancerous
MCF-10A cell line at 1 μMouabain. Notably, lower concentration of oua-
bain (100 nM) had no effect on cell proliferation in any of the cell lines
studied. However, we also observed a widely variable sensitivity of the
various cancer cell lines to the anti-proliferative effect of high doses of
ouabain. The basis for this variable response is not apparent but our
data would suggest that the presence or absence of the ER is not a dis-
criminating factor in determining ouabain sensitivity. The differences
in sensitivity to ouabain may lie in the observation that the cell lines
most sensitive to ouabain, T47D and MDA-MB231 cells, had higher
Na–K α3 to α1 subunit ratio.
In summary, our data demonstrates for the ﬁrst time the absence of
Na–K in ER negative highlymetastatic cancer cells, MDA-MB453, which
occurs in parallel with high V-ATPase activity and high hERG and
KCNQ2potassiumchannel expression. The ﬁndings suggest that for cer-
tain tumors V-ATPase and other potassium channels like KCNQ2may be
a target for cancer therapy. In the other breast cancer cells, which do ex-
press Na–K, the antiproliferative effect of ouabain was signiﬁcant but
not more pronounced than in non-cancer cells. It is noteworthy that
breast cancer cells exhibit signiﬁcant heterogeneity in the expression
of transport proteins responsible for maintenance of intracellular ho-
meostasis. These differences suggest the presence of fundamental dif-
ferences in cancer cell metabolism that could potentially be exploited
for the development of new therapies for breast cancer. The differences
in the expression of Na–K subunits and the lack of cancer cell selectivityfor the antiproliferative effects of ouabain suggest that the application of
ouabain-like cardioglycosides for breast cancer may be limited.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.04.023.
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